The dual inhibitor FGTI-2734 impedes tumour cell growth and is expected to overcome the barrier of K-ras resistance.348 In addition, FGTI-2734 inhibits mast cell-dependent allergic reactions, which is a promising therapeutic strategy for allergic diseases.349 L-778,123 has been assessed in preclinical and clinical studies. Here, KRAS is linked to neoplasm.